ArticleJACC. Case reports2025
Multimodal Diagnostic Approach in Cardiac Myeloid Sarcomas.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyeloid sarcomas are rare extramedullary infiltrations of immature myeloid cells seen in leukemic, myeloproliferative, and myelodysplastic syndromes. Cardiac infiltration of these cells clinically manifest based on the heart anatomy that is affected. CASE SUMMARY: A 61-year-old male with significant history of acute myeloid leukemia status post hematopoietic stem cell transplant, left renal myeloid sarcoma status post chemoradiation, and left eye myeloid sarcoma status post chemoradiation was found to have new cardiac myeloid sarcomas (CMS) after presenting with subacute chest pain and new onset of atrioventricular nodal disease on electrocardiogram. DISCUSSION: While obtaining an endomyocardial biopsy is the gold standard for diagnosing CMS, multiple diagnostic modalities can be used to determine the presence of them. TAKE-HOME MESSAGE: While CMS is rare, it is important to follow through with a multimodal diagnostic approach to clarify the diagnosis in the at-risk malignant hematological population when presenting with new or changing cardiac clinical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.